Notable
MSTH-CAR002 · This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy · Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma
Enrolling by invitation only
Also in this update: Study completion pushed from Dec 2031 to Dec 2032
Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyPhase 1/2 NCT07162571 Registry history of NCT07162571 on ClinicalTrials.gov (opens the registry)